ELISA/ACT Biotechnologies began in 1984 with the Lymphocyte Response Assay (LRA) test, which focused on detecting delayed hypersensitivities.
ELISA/ACT Biotechnologies has developed methods to collect, transport, and process live lymphocytes with the LRA and can provide comprehensive information about a patient’s lymphocyte reaction directly, yielding data on the three delayed hypersensitivity pathways:
This helps identifies a patient’s immune response to specific environmental and microbial antigens and can include such immune system triggers as food, color agents, and chemicals.
ELISA/ACT Biotechnologies’ testing and treatment plans have been beneficial in supporting conditions such as asthma, migraines, IBS, diabetes, and fibromyalgia. Results from the LRA tests are helpful for the management of immune system disorders involving chronic inflammation and autoimmunity.
ELISA/ACT Biotechnologies strives to promote a proactive approach to preventing immune system issues while providing testing and treatment plans to support patients.
Their vision is to support a greater movement towards using “predictive goal values” rather than simply relying on the conventional “usual lab ranges.”
Their testing methods yield high reproducibility and have the greatest number of test items available for delayed hypersensitivity.
ELISA/ACT Biotechnologies’ diagnostic testing, research development, and patient-practitioner support arise from healthcare expertise in clinical medicine, biochemistry, immunology, methodology, integrative health policy, and nutrition.
ELISA ACT specializes in their lymphocyte response assay for detecting delayed hypersensitivities.